Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to assess the capability of a patient with Chronic
Lymphocytic Leukemia (CLL) or Waldenström Macroglobulinemia (WM) to generate an immune
response to the Shingrix vaccine under first-line BTK inhibitors.